Intravenous administration was more efficacious than intradermal delivery in protecting rhesus macaques from Mycobacterium tuberculosis.
The currently licensed tuberculosis (TB) vaccine, intradermally delivered live-attenuated Mycobacterium bovis (BCG), has shown mixed results in protecting adults and adolescents from pulmonary TB. One possible reason is that intradermal vaccination does not elicit high frequencies of protective T cell responses in the lung, which is where Mycobacterium tuberculosis (Mtb) enters the body. Now, investigators have evaluated whether systemic administration of BCG might be better at inducing protective immunity in an animal model.
Rhesus macaques were vaccinated with BCG by intradermal (ID) or intravenous (IV) routes.
IV delivery induced substantial increases in T cells in bronchoalveolar lavage samples, whereas ID delivery did not. IV BCG also el…
Reviewing Author
DisclosuresGrant/Research SupportNIH
Editorial BoardsUpToDate; ID Images (idimages.org); Infectious Diseases Society of America COVID-19 Treatment Guidelines; International Antiviral Society–USA (Guidelines Committee)
Leadership Positions in Professional SocietiesHIV Medicine Association; Infectious Diseases Society of America (Board of Directors)
DisclosuresGrant/Research SupportNIH
Editorial BoardsUpToDate; ID Images (idimages.org); Infectious Diseases Society of America COVID-19 Treatment Guidelines; International Antiviral Society–USA (Guidelines Committee)
Leadership Positions in Professional SocietiesHIV Medicine Association; Infectious Diseases Society of America (Board of Directors)